

- **Name:** Young Saing Kim
  - **Current Position & Affiliation:** Associate Professor, Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
  - **Country:** Korea
- 

- **Educational Background:**

March 9, 1998 – February 20, 2004

Graduated from Gachon University College of Medicine, Incheon, Korea

March 2, 2007 – February 28, 2009

Master of Medical Science, Gachon University Graduate School, Incheon, Korea  
Department of Internal Medicine

March 2, 2015 – February 23, 2017

Doctor of Philosophy, Gachon University Graduate School, Incheon, Korea  
Department of Internal Medicine

- **Professional Experience:**

March 2014 – May 2015

Clinical Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea

June 2015 – August 2020

Assistant Professor, Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

September 2020 – Present

Associate Professor, Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

November 2018 – July 2020

Director of Gachon Clinical Trial Center, Gil Medical Center, Incheon, Republic of Korea

September 2021 – August 2022

Visiting Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA

- **Professional Organizations:**

March 2008 – Present

Member, Korean Society of Medical Oncology (KSMO)

March 2016 – Present

Member, Korean Cancer Study Group (KCSG)

December 2016 – Present

Member, Insurance and Policy Committee, KSMO

March 2019 – December 2023

Secretary of Rare Cancer Committee, KCSG

March 2017 – Present

Member, Korean Society of Gynecologic Oncology

March 2018 – Present

Member, International Association for the Study of Lung Cancer

May 2021 – Present

Member, Korean Gynecologic Oncology Group

• **Main Scientific Publications:**

Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06)

Cancer. 2025 Jan 1;131(1):e35609.

Choosing the right adjuvant therapy for stage III-IVA endometrial cancer: A comparative analysis of chemoradiotherapy and chemotherapy.

Gynecol Oncol. 2024 Jan 20;182:39-44.

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.

Oncologist. 2020 Jan;25(1):e186-e193

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer.

J Thorac Oncol. 2015 Dec;10(12):1795-9

The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.

Lung Cancer. 2013 Aug;81(2):231-5